

## René Russo

René Russo, Pharm.D., BCPS is the Chief Executive Officer at Arsanis, Inc, a biotechnology company focused on the development of human monoclonal antibodies for the prevention and treatment of serious infectious diseases. Prior to her role at Arsanis, Dr. Russo spent 11 years at Cubist Pharmaceuticals where she contributed to the successful launch and commercialization of daptomycin (reaching over \$1B worldwide) and held various positions culminating as Vice President, Global Medical Affairs where she led Global Medical Sciences, Clinical Microbiology, Health Economics/Outcomes Research and Field Medical Teams for a portfolio of anti-infective products. Dr. Russo played a key role in Cubist's successful integration of two public companies, Optimer and Trius, in 2013, as well as the launch of several recent important global antibiotics, ceftolozane/tazobactam, fidaxomicin and tedizolid. Prior to joining Cubist, Dr. Russo held various positions at Bristol-Myers Squibb in anti-infective Medical Operations and Clinical Pharmacology/ Experimental Medicine, where she made significant contributions to the development of several antibacterials, antifungals and anti-virals.

Dr. Russo received her Bachelor of Science in Pharmacy and Doctor of Pharmacy degrees from Rutgers University. She completed a postdoctoral industry fellowship in Infectious Diseases through Bristol-Myers Squibb and Rutgers University. Dr. Russo currently serves as a Director for Life Science Cares, an emerging nonprofit that engages leaders and companies in the space with giving back, and as a Trustee for Nashoba Brooks School.